AWP
AZN icon

Abacus Wealth Partners’s AstraZeneca AZN Stock Holding History

Abacus Wealth Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
6,508
+190
+3% +$36.6K 0.12% 79
2025
Q4 		$1.16M Buy
+6,318
New +$1.11M 0.11% 88

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Abacus Wealth Partners's AZN Position: Q1 2026 in Review

Abacus Wealth Partners increased its AstraZeneca (AZN) stake by 3% in Q1 2026, buying an estimated $36.6K and bringing the position to 6,508 shares worth $1.28M. The position accounts for 0.12% of the portfolio, ranked #79.

Abacus Wealth Partners first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Abacus Wealth Partners held 6,508 shares of AstraZeneca worth $1.28M as of Q1 2026.
  • Abacus Wealth Partners bought 190 AstraZeneca shares in Q1 2026, an estimated $36.6K.
  • AstraZeneca made up 0.12% of Abacus Wealth Partners's portfolio in Q1 2026, its #79 holding.
  • Abacus Wealth Partners first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Abacus Wealth Partners's 13F filing for Q1 2026, filed 24 Apr 2026.